



Hogan Lovells US LLP  
Columbia Square  
555 Thirteenth Street, NW  
Washington, DC 20004  
T +1 202 637 5600  
F +1 202 637 5910  
[www.hoganlovells.com](http://www.hoganlovells.com)

February 12, 2024

Division of Dockets Management  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, Maryland 20852

**Re: Docket No. FDA-2022-P-3318**

Dear Sir or Madam:

The undersigned, on behalf of Octapharma USA, Inc. and Octapharma Pharmazeutika Produktionsge mbH (collectively, Octapharma), hereby withdraws the above referenced citizen petition, filed on December 21, 2022. The citizen petition is being withdrawn pursuant to intervening events, but without prejudice to resubmission at any time. Pursuant to 21 CFR 10.30 (g), the withdrawal is timely filed and does not require Agency approval because the Commissioner has not yet ruled on the petition as of the date of this submission.

If you have any questions, please contact me at (202) 637-5635 or [Mike.Druckman@hoganlovells.com](mailto:Mike.Druckman@hoganlovells.com).

Respectfully submitted,

A handwritten signature in black ink that reads "Mike Druckman". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Mike Druckman, Partner  
Hogan Lovells US LLP  
555 13<sup>th</sup> Street NW  
Washington, DC 20004  
D: (202) 637-5635  
[Mike.Druckman@hoganlovells.com](mailto:Mike.Druckman@hoganlovells.com)  
*Counsel for Octapharma*

cc: Flemming Nielsen  
Octapharma